284 related articles for article (PubMed ID: 28945114)
1. Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation.
Liu S; Li X; Shi Q; Hamilton M; Friend K; Zhao Y; Horblyuk R; Hede S; Shi L
Curr Med Res Opin; 2018 Mar; 34(3):415-421. PubMed ID: 28945114
[TBL] [Abstract][Full Text] [Related]
2. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
Hirano T; Kaneko H; Mishina S; Wang F; Morita S
J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
[TBL] [Abstract][Full Text] [Related]
3. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis.
Vestergaard AS; Skjøth F; Larsen TB; Ehlers LH
PLoS One; 2017; 12(11):e0188482. PubMed ID: 29155884
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
[TBL] [Abstract][Full Text] [Related]
5. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
[TBL] [Abstract][Full Text] [Related]
6. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
8. Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study).
Hellyer JA; Azarbal F; Than CT; Fan J; Schmitt SK; Yang F; Frayne SM; Phibbs CS; Yong C; Heidenreich PA; Turakhia MP
Am J Cardiol; 2017 Jan; 119(2):268-274. PubMed ID: 27836133
[TBL] [Abstract][Full Text] [Related]
9. Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System.
An J; Niu F; Zheng C; Rashid N; Mendes RA; Dills D; Vo L; Singh P; Bruno A; Lang DT; Le PT; Jazdzewski KP; Aranda G
J Manag Care Spec Pharm; 2017 Jun; 23(6):700-712. PubMed ID: 28530526
[TBL] [Abstract][Full Text] [Related]
10. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.
Razouki Z; Ozonoff A; Zhao S; Jasuja GK; Rose AJ
Circ Cardiovasc Qual Outcomes; 2014 Sep; 7(5):664-9. PubMed ID: 25185245
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation.
Spivey CA; Qiao Y; Liu X; Mardekian J; Parker RB; Phatak H; Claflin AB; Kachroo S; Abdulsattar Y; Chakrabarti A; Wang J
J Manag Care Spec Pharm; 2015 Jul; 21(7):596-606. PubMed ID: 26108384
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB;
Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971
[TBL] [Abstract][Full Text] [Related]
13. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation.
Williams BA; Evans MA; Honushefsky AM; Berger PB
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29025746
[TBL] [Abstract][Full Text] [Related]
14. Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction.
Szummer K; Gasparini A; Eliasson S; Ärnlöv J; Qureshi AR; Bárány P; Evans M; Friberg L; Carrero JJ
J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28249846
[TBL] [Abstract][Full Text] [Related]
15. Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation.
Deitelzweig S; Evans M; Hillson E; Trocio J; Bruno A; Tan W; Lingohr-Smith M; Singh P; Lin J
Curr Med Res Opin; 2016; 32(1):87-94. PubMed ID: 26451675
[TBL] [Abstract][Full Text] [Related]
16. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation.
Yasaka M; Minematsu K; Yamaguchi T
Intern Med; 2001 Dec; 40(12):1183-8. PubMed ID: 11813841
[TBL] [Abstract][Full Text] [Related]
17. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.
Pokorney SD; Simon DN; Thomas L; Fonarow GC; Kowey PR; Chang P; Singer DE; Ansell J; Blanco RG; Gersh B; Mahaffey KW; Hylek EM; Go AS; Piccini JP; Peterson ED;
Am Heart J; 2015 Jul; 170(1):141-8, 148.e1. PubMed ID: 26093875
[TBL] [Abstract][Full Text] [Related]
18. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.
Haas S; Ten Cate H; Accetta G; Angchaisuksiri P; Bassand JP; Camm AJ; Corbalan R; Darius H; Fitzmaurice DA; Goldhaber SZ; Goto S; Jacobson B; Kayani G; Mantovani LG; Misselwitz F; Pieper K; Schellong SM; Stepinska J; Turpie AG; van Eickels M; Kakkar AK;
PLoS One; 2016; 11(10):e0164076. PubMed ID: 27792741
[TBL] [Abstract][Full Text] [Related]
19. Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice.
An J; Niu F; Lang DT; Jazdzewski KP; Le PT; Rashid N; Meissner B; Mendes R; Dills DG; Aranda G; Bruno A
J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26187996
[TBL] [Abstract][Full Text] [Related]
20. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry.
Lehto M; Niiranen J; Korhonen P; Mehtälä J; Khanfir H; Hoti F; Lassila R; Raatikainen P
Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):657-665. PubMed ID: 28317274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
